anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Alternative therapies and herbal remedies are increasingly recognized as having therapeutic value, and as many as 42% adults use some form of complementary and alternative medicine (CAM). The prevalence of CAM use among adolescents is not known. Questions remain about the safety and efficacy of some CAM therapies, and how to best facilitate communication about alternative medicine between patients and clinicians. Research with adults shows that most do not reveal their use of alternative therapies to their providers. Adolescence is a time of experimentation and the beginning of a shift from depending upon parents to taking responsibility for one's own care. Thus, the health practices begun in adolescence have an impact into adulthood. However, none of the current guidelines for the provision of care to adolescents advise asking about complementary or alternative medicine use. Finally, adolescents are exposed to increasing coverage of CAM in the media, and on the internet. The specific aims of this study are to: 1) determine the prevalence of complementary and alternative medicine use among a representative sample of adolescents, 2) describe the range of therapies adolescents use, and where they are procured, 3) describe adolescent and clinician factors that are associated with communication between adolescents and their providers about complementary and alternative medicine, and 4) describe adolescents' exposure to information about CAM from sources such as parents, providers, and the media, and how this impacts CAM use. We propose a cross sectional random digit dial telephone survey of 1200 adolescents in Monroe County, NY. Our findings will allow us to understand how adolescents use alternative medicine. Additionally, since alternative therapies can have potentially serious side-effects or drug interactions, insight into how and when alternative medicine use is disclosed may help clinicians provide better care to adolescents.
A single dose of Atomoxetine (ATX) (40 mg) will be administered. Supplied as 1 over-encapsulated pill of 40 mg plus 1 placebo capsule.
Midazolam 1mg/ml, solution for injection / infusion. Each 5ml ampoule contains 5mg midazolam. Concentration: 1mg/ml.
FIELD: molecular biology, genetic and protein engineering, medicine, pharmacy. SUBSTANCE: invention relates to polypeptide variants eliciting with the enhanced heparin-binding capacity. The enhanced heparin-binding capacity is achieved by insertion of amino acid sequence and/or substitution for amino acid sequence RKRA (SEQ ID NO:3 or RKRAKHKQ (SEQ ID NO:4) in amino acid sequence of polypeptide taken among members of superfamily TGF-β. These polypeptide variants are especially useful for stimulation of chondrogenesis, osteogenesis and wounds healing. Invention relates also to nucleic acid molecules that encode polypeptide variants, host-cells comprising nucleic acid molecules and to method for preparing polypeptide variants and to pharmaceutical compositions also. The advantage of the invention involves the development of novel preparations that can be used for stimulation of reparative processes of osteogenesis and chondrogenesis. EFFECT: valuable medicinal properties of polypeptides. 25 cl, 10 dwg, 1 tbl
Vertebrates have expanded their habitats during evolution, which accompanies diversified routes for water acquisition. Water is acquired by oral intake and subsequent absorption by the intestine in terrestrial and marine animals which are subjected to constant dehydration, whereas most water is gained osmotically across body surfaces in freshwater animals. In addition, a significant amount of water, called metabolic water, is produced within the body by the oxidation of hydrogen in organic substrates. The importance of metabolic water production as a strategy for water acquisition has been well documented in desert animals, but its role has attracted little attention in marine animals which also live in a dehydrating environment. In this article, the author has attempted to reevaluate the role of metabolic water production in body fluid regulation in animals inhabiting desiccating environments. Because of the exceptional ability of their kidney, marine mammals are thought to typically gain water by drinking environmental seawater and excreting excess NaCl in the urine. On the other hand, it is established that marine teleosts drink seawater to enable intestinal water and ion absorption, and the excess NaCl is excreted by branchial ionocytes. In addition to the oral route, we suggest through experiments using eels that water production by lipid metabolism is an additional route for water acquisition when they encounter seawater. It seems that metabolic water production contributes to counteract dehydration before mechanisms for water regulation are reversed from excretion in freshwater to acquisition in seawater.
Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) salivary sample and serum will be taken from all individuals at the beginning of the study. ANGPTL-4 levels will be examined to evaluate before and after treatment in periodontal health and periodontitis. A pre-treatment saliva sample and serum will be collected from the clinically healthy group.
Participants will be asked to maintain their normal activities and diet. They will be added to a waiting list to receive either exercise intervention after completing the 24-week trial period, so that they do not miss out on the opportunity to receive the exercise intervention.
Hashimoto thyroiditis is an autoimmune disease that leads to chronic inflammation of the thyroid gland. This is considered the most common autoimmune disorder, and the most common endocrine disorder. Psychological trauma has been suggested as a possible factor in the pathogenesis and development of autoimmune diseases. Although a diversity of psychotherapeutic interventions have been studied in adults with autoimmune diseases, there is a lack of psychological research and randomized controlled trials in the field of the Hashimoto disease. This study is designed to be a clinical trial with two arms: one experimental and one control group. The experimental group receives IOPT and the control group is a waiting list. 70 out-patients with Hashimoto disease will be randomly assigned to the two groups. The investigators hypothesize that the therapeutic gains will be more significant in the experimental condition than in the control groups at the completion of the therapy and that this will be maintained at the 3-month follow-up.The IOPT group undergoes 10 group modules of IOPT once at two weeks.The sessions will be conducted by clinicians or psychotherapists specialized in IOPT. If therapy is efficient on the autoimmune disorder, participants in the control group will be reallocated to IOPT after the experimental treatment will come to an end.
OBJECTIVES: I. Determine the response in patients with androgen-independent prostate cancer treated with calcitriol and carboplatin. II. Determine the palliative response in patients with cancer-related pain treated with this regimen. III. Determine the response in patients with bidimensionally measurable disease treated with this regimen. IV. Determine the duration of prostate-specific antigen, palliative, and measurable disease responses in patients treated with this regimen. V. Determine the survival of patients treated with this regimen. VI. Assess the quality of life of patients treated with this regimen. VII. Determine the qualitative and quantitative toxic effects of this regimen in these patients.

OUTLINE: Patients receive oral calcitriol on day 1 and carboplatin IV over 60 minutes on day 2. Treatment repeats every 28 days in the absence of unacceptable toxicity or disease progression. Quality of life is assessed at baseline and then every 4 weeks until disease progression. Patients are followed every 4 weeks until disease progression and then every 3 months thereafter.

PROJECTED ACCRUAL: A total of 18-36 patients will be accrued for this study.
Methods, systems, and apparatus, including computer programs encoded on computer storage media, to present a video. One of the methods includes obtaining one or more unstructured documents. The method includes obtaining, by a computer system, a data model, the data model identifying a type of fact that can be determined from the one or more unstructured documents. The method includes determining, by the computer system, a channel to extract facts from the document based on the type of fact. The method includes distributing, by the computer system, the one or more unstructured documents to the channel. The method includes extracting, by the channel, facts from the one or more unstructured documents. The method also includes storing the facts in a data model.
Voriconazole is metabolized by cytochrome P450 isoenzymes, CYP2C19, CYP2C9, and CYP3A4. Therefore, inhibitors or inducers of these isoenzymes may increase or decrease voriconazole plasma concentrations, respectively. Voriconazole is a strong inhibitor of CYP3A4, and also inhibits CYP2C19 and CYP2C9. Therefore, voriconazole may increase the plasma concentrations of substances metabolized by these CYP450 isoenzymes.

Tables 10 and 11 provide the clinically significant interactions between voriconazole and other medical products.

Table 11: Effect of Voriconazole on Pharmacokinetics of Other Drugs [see Clinical Pharmacology (12.3)]
Stressful circumstances are significant contributors to mental illnesses such as major depressive disorder. Anhedonia, defined as loss of the ability to enjoy pleasure in pleasurable situations, including rewarding activities or social contexts, is considered a key symptom of depression. Although stress-induced depression is associated with anhedonia in humans and animals, the underlying molecular mechanisms of anhedonic responses remain poorly understood. In this study, we demonstrated that synaptotagmin-4 (SYT4), which is involved in the release of neurotransmitters and neurotrophic factors, is implicated in chronic stress-induced anhedonia. Employing chronic unpredictable stress (CUS), we evaluated two subpopulations of mice, susceptible (SUS, anhedonic) and resilient (RES, nonanhedonic), based on sucrose preference, which was strongly correlated with social reward. The FosTRAP (targeted recombination in active populations) system and optogenetic approach revealed that neural activity in the medial prefrontal cortex (mPFC) was significantly associated with CUS-induced anhedonic behavioral phenotypes. By conducting weighted gene coexpression network analysis of RNA sequencing data from the mPFC of SUS and RES mice, we identified Syt4 as a hub gene in a gene network that was unique to anhedonia. We also confirmed that Syt4 overexpression in the mPFC was pro-susceptible, while Syt4 knockdown was pro-resilient; the pro-susceptible effects of SYT4 were mediated through a reduction in brain-derived neurotrophic factor (BDNF)-tropomyosin receptor kinase B (TrkB) signaling in the mPFC. These findings suggest that SYT4-BDNF interactions in the mPFC represent a crucial regulatory mechanism of anhedonic susceptibility to chronic stress.
The invention discloses an ointment for treating skin burns and scalds, belonging to the field of traditional Chinese medicine. The ointment is prepared from the following raw materials in parts by weight: 1 part of quicklime, 10-15 parts of sesame oil, 0.2-0.5 part of aloe juice, 0.1-0.3 part of peppermint oil and 20-25 parts of water. In the formula adopted by the invention, the quicklime and the sesame oil have the functions of stopping pain, eliminating swelling and promoting healing of burns and scalds; the aloe juice has the functions of converging, softening and moisturizing the skin and diminishing inflammation; and the peppermint oil has the functions of clearing away heat, dispersing pathogenic wind, preventing corrosion, diminishing inflammation, stopping pain and relieving itching. The ointment disclosed by the invention has a reasonable and scientific prescription, has the functions of clearing away heat and toxic material, removing necrosis to promote tissue regeneration, activating blood circulation to dissipate blood stasis, eliminating swelling to stop pain and the like for burns, and has an excellent effect on treating skin burns and scalds in the initial stage. The ointment has the advantages of high effect taking speed, high pain stopping speed, simple preparation method and low cost, can not cause infection easily, and is convenient to use and popularize. After the ointment is applied on the affected part, pain, itching or scars can not be caused on the affected part. The invention solves the problem that when the traditional medicaments are used for treating burns and scalds, patients are painful.
PURPOSE: To obtain the subject low-toxic promoter containing, as active ingredient, pseurotin A, having PC12 cell projectional extension promotive activity, thus useful as an anti-demential agent, or a peripheral nerve disorder therapeutic agent or neurocyte protective agent in carcinostatic therapies. CONSTITUTION: This promoter contains, as active ingredient, pseurotin A of the formula or a salt thereof. The content of the compound of the formula in this promoter is pref. 1-10wt.% in the case of injection, 25-98wt.% for capsules, tablets, granules or powder. The amount of this promoter to be used in therapy is normally 1-100mg/kg b.w. a day for parenteral administration, 5-500mg/kg b.w. a day for oral administration. It is recommended that the compound of the formula be obtained by culturing the pseurotin A-productive fungi belonging to Diheterospora by deep aerating agitation culture method followed by isolation from the resultant culture filtrate. The pseurotin A- productive fungi is pref. Diheterospora chlamydosporia NFO1150 (FERM P-14736).
Part 1 will identify the recommended Part 2 dose using a dose-escalation procedure. Escalation may proceed until either a maximum tolerated dose is established, or the toxicokinetic safety limit is reached. Subjects may dose up to three times a day.
Patients in the UC arm will not receive the study intervention (behavioral) and instead will receive care according to usual practice. This usually involves a brief office visit (approximately 5-10 minutes) with pertinent history and physical examination related to surgical/radiation recovery, review of the pathology and general instructions regarding the next step in follow-up.
Rationale: Neovascular ocular diseases (NODs) represent the leading cause of visual impairment globally. Despite significant advances in anti-angiogenic therapies targeting vascular endothelial growth factor (VEGF), persistent challenges remain prevalent. As a proof-of-concept study, we herein demonstrate the effectiveness of targeted degradation of VEGF with bispecific aptamer-based lysosome-targeting chimeras (referred to as VED-LYTACs). Methods: VED-LYTACs were constructed with three distinct modules: a mannose-6-phosphate receptor (M6PR)-binding motif containing an M6PR aptamer, a VEGF-binding module with an aptamer targeting VEGF, and a linker essential for bridging and stabilizing the two-aptamer structure. The degradation efficiency of VED-LYTACs via the autophagy-lysosome system was examined using an enzyme-linked immunosorbent assay (ELISA) and immunofluorescence staining. Subsequently, the anti-angiogenic effects of VED-LYTACs were evaluated using in vitro wound healing assay, tube formation assay, three-dimensional sprouting assay, and ex vivo aortic ring sprouting assay. Finally, the potential therapeutic effects of VED-LYTACs on pathological retinal neovascularization and vascular leakage were tested by employing mouse models of NODs. Results: The engineered VED-LYTACs promote the interaction between M6PR and VEGF, consequently facilitating the translocation and degradation of VEGF through the lysosome. Our data show that treatment with VED-LYTACs significantly suppresses VEGF-induced angiogenic activities both in vitro and ex vivo. In addition, intravitreal injection of VED-LYTACs remarkably ameliorates abnormal vascular proliferation and leakage in mouse models of NODs. Conclusion: Our findings present a novel strategy for targeting VEGF degradation with an aptamer-based LYTAC system, effectively ameliorating pathological retinal angiogenesis. These results suggest that VED-LYTACs have potential as therapeutic agents for managing NODs.
Blood samples will be collected at 0 hours (before randomization). Blood samples will then be collected at 6 hours post randomization and 24 hours post randomization. These patients will not receive daily RIC therapy but will only have their blood drawn once daily during the patients' length of stay up to a maximum of 7 days.
PURPOSE: To maintain the free flow state of a feedstock with a nonsolubilized carrier before it is solidified, thereby obtaining a shearform matrix with a large volume, by increasing the temperature of the feedstock to a point where the carrier generates an internal flow when the carrier is subjected to a fluid shear force. CONSTITUTION: The feedstock 18 is discharged from an extruder 10 and is advanced via a valve mechanism 32. The feedstock is subjected to shearing while it is in the internal flow state by ejecting a high speed air flow against an interference flow coming out of a nozzle 34. The high speed air is given by the air flow 42, which is introduced into an inline heater 44 and a thermocouple 43 through a filter/pressure flow controller 41 to control the temperature thereof. The inline heater 44 is used to raise the air temperature and enhance the feature of a free flow of masses which are separated from a stream of the feedstock and are sheared. The air is preferably heated from about 130 deg.C to about 210 deg.C for cane sugar and from about 85 deg. to about 180 deg.C for maltodextrin.
OBJECTIVE: The COVID-19 pandemic has had a strong impact on other infectious diseases. The aim of this paper was to analyze the epidemiological changes that occurred during the pandemic in eight infectious diseases with different epidemiological patterns: influenza, respiratory syncytial virus, rotavirus, pneumococcus, Campylobacter, non-typhoid Salmonella, gonorrhea and herpes zoster.
METHODS: From the Microbiological Surveillance Network, the time series of cases was traced from January 2017 to March 2023. Three periods were distinguished: reference, pandemic and beginning of the post-pandemic. The distribution by age and sex in these periods was analyzed. Incidence rates and rate ratios (RR) were calculated. These RRs and their 95% confidence intervals were estimated overall and by year of age in children under five years of age.
RESULTS: Statistically significant differences were found in the impact that the pandemic had on each of these diseases. Some, after a period of epidemic silence, have revealed an intense post-pandemic rebound. The post-pandemic global RT increased for influenza (2.4), RSV (1.9) and gonorrhea (3.1); rotavirus recovered its pre-pandemic level (1.07); and pneumococcus (0.84), Campylobacter (0.83) and Salmonella (0.60) decreased. In children under 5 years of age, the patterns were specific and heterogeneous for each disease.
CONCLUSIONS: The impact of the pandemic is very different in these diseases. Pediatric and respiratory-transmitted seasonal viral infections are the ones that are most affected, but with different patterns of recovery to normality. Gastrointestinal bacterial infections suffer fewer variations, except for rotavirus. Gonorrhea do not interrupt its increasing trend seen in the pre-pandemic. Shingles show a slight post-pandemic increase. Several diseases with different epidemiological patterns have been studied for a sufficient period to observe how the acute phase of the pandemic emerges.
RATIONALE: Unintentional weight loss and malnutrition are common among cancer patients. Malnutrition has been associated with impaired health-related quality of life, less well-tolerated chemotherapy regimens and shorter life duration. In Belgium there is a lack of epidemiological data on malnutrition in oncology patients at advanced stages of the disease.
METHODS: Malnutrition assessment data was collected through a prospective, observational study in 328 patients who started a neoadjuvant anticancer therapy regimen or who started 1st, 2nd or 3rd line anticancer therapy for a metastatic cancer via 3 visits according to regular clinical practice (baseline visit (BV) maximum 4 weeks before start therapy, 1st Follow up visit (FUV1) ± 6 weeks after start therapy, FUV2 ± 4 months after start therapy). Malnutrition screening was evaluated using the Nutritional Risk Screening score 2002 (NRS-2002)and the diagnosis of malnutrition by the GLIM criteria. In addition, SARC-F questionnaire and Fearon criteria were used respectively to screen for sarcopenia and cachexia.
RESULTS: Prevalence of malnutrition risk at BV was high: 54.5% of the patients had a NRS ≥ 3 (NRS 2002) and increased during the study period (FUV1: 73.2%, FUV2: 70.1%). Prevalence of malnutrition based on physician subjective assessment (PSA) remained stable over the study period but was much lower compared to NRS results (14.0%-16.5%). At BV, only 10% of the patients got a nutrition plan and 43.9% received ≤ 70% of nutritional needs, percentage increased during FU period (FUV1: 68.4%, FUV2: 67.6%). Prevalence of sarcopenia and cachexia were respectively 12.4% and 38.1% at BV and without significant variation during the study period, but higher than assessed by PSA (11.6% and 6.7% respectively). Figures were also higher compared to PSA. There were modifications in cancer treatment at FUV1 (25.2%) and at FUV2 (50.8%). The main reasons for these modifications at FUV1 were adverse events and tolerability. Patient reported daily questionnaires of food intake showed early nutritional deficits, preceding clinical signs of malnutrition, and therefore can be very useful in the ambulatory setting.
CONCLUSIONS: Prevalence of malnutrition and cachexia was high in advanced cancer patients and underestimated by physician assessment. Earlier and rigorous detection of nutritional deficit and adjusted nutritional intake could lead to improved clinical outcomes in cancer patients. Reporting of daily caloric intake by patients was also very helpful with regards to nutritional assessment.
The present invention provides methods and compositions for attenuating expression of a target gene in vivo. In general, the method includes administering RNAi constructs (such as small-interfering RNAs (i.e., siRNAs) that are targeted to particular mRNA sequences, or nucleic acid material that can produce siRNAs in a cell), in an amount sufficient to attenuate expression of a target gene by an RNA interference mechanism. In particular, the RNAi constructs may include one or more modifications to improve serum stability, cellular uptake and/or to avoid non-specific effect. In certain embodiments, the RNAi constructs contain an aptamer portion. The aptamer may bind to human serum albumin to improve serum half life. The aptamer may also bind to a cell surface protein that improves uptake of the construct.